Overview

Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual tablets after consumption of a high-fat meal.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Metformin
Sitagliptin Phosphate